Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | FPR2 | P25090 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FPR3 | P25089 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24575914 | 0.83 | TGM2 (0.63) | TGM2L3MBTL1MEN1KMT2ACA1 | |
| SCHEMBL626651 | 0.81 | TPSAB1 (0.70) | CYP2C9CYP2C19MEN1KMT2ARECQL | |
| SCHEMBL8139643 | 0.81 | CYP2C9 (0.68) | CYP2C9CYP2C19L3MBTL1MEN1KMT2A | |
| SCHEMBL1694370 | 0.81 | L3MBTL1 (0.62) | CYP2C9CYP2C19TGM2L3MBTL1MEN1 | |
| SCHEMBL8245710 | 0.81 | CYP2C9 (0.68) | CYP2C9CYP2C19MEN1KMT2ARECQL | |
| SCHEMBL27589884 | 0.81 | CYP2C9 (0.68) | CYP2C9CYP2C19MEN1KMT2ACA1 | |
| SCHEMBL26547106 | 0.80 | TGM2 (0.47) | CYP2C9CYP2C19TGM2L3MBTL1MEN1 | |
| SCHEMBL5840627 | 0.80 | CNR1 (0.54) | MEN1KMT2AFPR2ALDH1A1HPGD | |
| SCHEMBL22466338 | 0.79 | CYP2C9 (0.66) | CYP2C9CYP2C19MEN1KMT2ACA1 | |
| SCHEMBL20715702 | 0.79 | CYP2C9 (0.66) | CYP2C9CYP2C19MEN1KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117946033-A | Preparation method for photo-promoted synthesis of urea compound | 兰州大学 | 2024-04-30 | — | — | CN | claimed |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2023-06-22 | — | — | US | claimed |
| EP-4081299-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2022-11-02 | — | — | EP | claimed |
| WO-2021130255-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-01 | — | — | WO | claimed |
| US-8729031-B2 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2014-05-20 | — | — | US | claimed |
| EP-2393829-A1 | ACTAGARDINE DERIVATIVES | Novacta Biosystems Limited (GB) | 2011-12-14 | — | — | EP | claimed |
| US-20110294723-A1 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-12-01 | — | — | US | claimed |
| WO-2010089544-A1 | ACTAGARDINE DERIVATIVES | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-08-12 | — | — | WO | claimed |
| WO-2025042989-A1 | PSMA-BASED ALBUMIN BINDING AGENTS FOR TARGETED RADIONUCLIDE THERAPY OF PROSTATE CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-02-27 | — | — | WO | disclosed |
| CN-117946033-A | Preparation method for photo-promoted synthesis of urea compound | 兰州大学 | 2024-04-30 | — | — | CN | disclosed |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2023-06-22 | — | — | US | disclosed |
| EP-4081299-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2022-11-02 | — | — | EP | disclosed |
| WO-2021130255-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-01 | — | — | WO | disclosed |
| CN-105283454-B | Quinazoline and azepine quinazoline as RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/MTOR access double inhibitor | ASANA BIOSCIENCES, LLC (US) | 2019-10-29 | — | — | CN | disclosed |
| EP-2393829-A1 | ACTAGARDINE DERIVATIVES | Novacta Biosystems Limited (GB) | 2011-12-14 | — | — | EP | disclosed |
| US-20110294723-A1 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-12-01 | — | — | US | disclosed |
| WO-2010089544-A1 | ACTAGARDINE DERIVATIVES | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-08-12 | — | — | WO | disclosed |
| US-20090233968-A1 | INHIBITORS OF THE ALPHA2BETA1/GPIa-IIA INTEGRIN | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090233968-A1 | INHIBITORS OF THE ALPHA2BETA1/GPIa-IIA INTEGRIN | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-09-17 | — | — | US | disclosed |
| WO-2006133338-A1 | INHIBITORS OF THE α2β1/GPIa-IIa INTEGRIN | THE TRUSTEES OF THE UNIVERSITY OF PENNESYLVANIA (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233968-A1 | INHIBITORS OF THE ALPHA2BETA1/GPIa-IIA INTEGRIN | ITGA2B, ITGB2, ITGA2 | CYP2C9 2405/4885CYP2C19 2679/4885TGM2 963/4885 |
| US-20110294723-A1 | Compounds | SLC11A2, SDHA, SDHB | CYP2C9 102/4885CYP2C19 66/4885TGM2 2282/4885 |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | FCER2, FCGR2A, FCGR1A | CYP2C9 2259/4885CYP2C19 1137/4885TGM2 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.